Want to see INBX full AI Analyst Report?
INBX Stock Chart & Stats
$122.72
$2.17(2.66%)
At close: 4:00 PM EDT
$122.72
$2.17(2.66%)
Day’s Range― - ―
52-Week Range$26.19 - $155.29
Previous CloseN/A
Volume61.50K
Average Volume (3M)255.53K
Market Cap
$1.80B
Enterprise Value$1.53K
Total Cash (Recent Filing)$133.34M
Total Debt (Recent Filing)$5.34M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 13, 2026EPS Estimate
-2.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.88
Shares Outstanding14,717,660
10 Day Avg. Volume316,610
30 Day Avg. Volume255,525
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$266.67Price Target Upside117.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Ozekibart Regulatory Progress And Differentiated Clinical DataBLA acceptance creates a defined path toward potential approval, while the randomized trial’s progression-free-survival benefit supports clinical differentiation. If approved, ozekibart could become the company’s first commercial product in a rare cancer with substantial unmet need.
Expanded Financing Capacity Supports Clinical ExecutionAdditional committed borrowing capacity can extend the runway for ozekibart and INBRX-106 development and reduce near-term dependence on public equity markets. This improves execution flexibility as the company approaches important clinical and regulatory milestones.
Pipeline Expansion Across Additional Hard-to-treat CancersTesting ozekibart in multiple tumor settings creates potential indications beyond chondrosarcoma and could broaden the addressable market. A wider clinical footprint may improve the pipeline’s strategic value if efficacy and safety are replicated across additional cancers.
Bears Say
No Durable Commercial Revenue BaseThe absence of recurring product revenue leaves the business dependent on future approvals, partnerships, or financing to fund operations. This limits revenue visibility over the next several quarters and makes progress toward commercialization central to fundamental performance.
Persistent Losses And Heavy Cash BurnLarge operating losses and sustained negative free cash flow show that current activities do not self-fund. Continued clinical development will require substantial external capital, increasing sensitivity to financing terms and execution delays before any product revenue arrives.
Negative Equity And Financing-related Dilution RiskNegative equity reduces financial flexibility and signals accumulated balance-sheet strain. Although reported TTM debt was lower, prior leverage volatility and the new facility’s warrants and collateral pledges indicate that additional funding may carry dilution or asset-risk consequences.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences Inc’s price range in the past 12 months?
Inhibrx Biosciences Inc lowest stock price was $26.19 and its highest was $155.29 in the past 12 months.
What is Inhibrx Biosciences Inc’s market cap?
Inhibrx Biosciences Inc’s market cap is $1.80B.
When is Inhibrx Biosciences Inc’s upcoming earnings report date?
Inhibrx Biosciences Inc’s upcoming earnings report date is Nov 13, 2026 which is in 69 days.
How were Inhibrx Biosciences Inc’s earnings last quarter?
Inhibrx Biosciences Inc released its earnings results on Aug 13, 2026. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$2.28 by -$0.06.
Is Inhibrx Biosciences Inc overvalued?
According to Wall Street analysts Inhibrx Biosciences Inc’s price is currently Undervalued.
Does Inhibrx Biosciences Inc pay dividends?
Inhibrx Biosciences Inc pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences Inc dividends here
What is Inhibrx Biosciences Inc’s EPS estimate?
Inhibrx Biosciences Inc’s EPS estimate is -2.45.
How many shares outstanding does Inhibrx Biosciences Inc have?
Inhibrx Biosciences Inc has 14,717,660 shares outstanding.
What happened to Inhibrx Biosciences Inc’s price movement after its last earnings report?
Inhibrx Biosciences Inc reported an EPS of -$2.34 in its last earnings report, missing expectations of -$2.28. Following the earnings report the stock price went down -8.906%.
Which hedge fund is a major shareholder of Inhibrx Biosciences Inc?
Currently, no hedge funds are holding shares in INBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibrx Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$266.67 (117.30% Upside)
$266.67 (117.30% Upside)
Blogger Sentiment
Bullish
INBX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 332.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
339.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.29%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inhibrx Biosciences Inc
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
INBX Stock 12 Month Forecast
Average Price Target
$266.67
▲(117.30% Upside)
Technical Analysis
Ownership Overview
9.63% Insiders
8.30% Mutual Funds
44.02% Other Institutional Investors
26.05% Public Companies and
Individual Investors